Pacific Edge (PEB) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with a welcome, introductions of board members, and confirmation of quorum; conducted both in-person and online.

• Agenda included financial review, Q&A, and voting on resolutions, following the notice sent to shareholders.

• Minutes of previous meetings were available for inspection.

Financial performance review

• FY25 operating revenue was $21.8M, down 8.6% year-on-year; laboratory throughput was 28,894 tests, down 11.5%.

• Net loss after tax was $29.9M; cash and equivalents stood at $22.6M.

• Average U.S. sales price increased to $594; cash collections improved.

• US commercial test volumes in 2H25 increased 2.7% over 1H25, supported by contracted payer volumes.

• Capital raise of $20.7M extended cash runway for over 12 months.

Board and executive committee updates

• Chairman Chris Gallaher agreed to remain in role for stability amid leadership succession challenges.

• Board includes Sarah Park, Anatole Masfen, Bryan Williams, Anna Stove, and Tony Barclay.

• Directors Sarah Park and Tony Barclay stood for reelection, emphasizing governance and financial oversight.

• CEO and Chairman delivered key addresses, focusing on strategic direction and operational resilience.

• Board highlighted strengthened governance, risk management, and capital discipline.